Literature DB >> 27543549

Reversal by the specific antidote, idarucizumab, of elevated dabigatran exposure in a patient with rectal perforation and paralytic ileus.

C Thorborg1, E-P Horn2, H Mofid2, F Langer3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27543549     DOI： 10.1093/bja/aew244

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN： 0007-0912            Impact factor:   9.166


× No keyword cloud information.
  3 in total

1.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

2.  Comment on: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".

Authors:  Kirollos S Kamel; Paul K L Chin; Matthew P Doogue; Murray L Barclay
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447

3.  Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage.

Authors:  Jonathan Balakumar; Ruben Santiago; Mark Supino
Journal:  Clin Pract Cases Emerg Med       Date:  2017-10-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.